Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 38
States / cities: Fresno, California • Greenbrae, California • Huntington Beach, California + 33 more

Conditions: Coronary Artery Disease, Coronary Atherosclerosis
Interventions: CYPHER® ELITE™ Sirolimus-Eluting Stent System, CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Hepatitis B
Interventions: Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Stroke, Traumatic Brain Injury, Multiple Sclerosis, Spasticity, Healthy Controls
Interventions: Not listed
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SHP465, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Dothan, Alabama • Orange, California • San Diego, California + 31 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide 7.5 mg; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 23
States / cities: Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more

Conditions: Skin Diseases, Bacterial
Interventions: Intravenous iclaprim, Intravenous linezolid; Drug
Lead sponsor: Arpida AG; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Naperville, Illinois • Casper, Wyoming

Conditions: Multiple Sclerosis, Chronic Pain, Fatigue
Interventions: Intervention #1, Intervention #2, Intervention #3; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more

Conditions: Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions: Not listed
Lead sponsor: Bastyr University; Other
Eligibility: 19 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Osteoarthritis, Knee
Interventions: JointStem, Placebo Control; Drug · Other
Lead sponsor: Nature Cell Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: El Cajon, California • La Mesa, California • Napa, California + 2 more

Conditions: Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions: ozarelix, Placebo; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Chronic Low Back Pain
Interventions: Oxycodone DETERx, Placebo; Drug
Lead sponsor: Collegium Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Urinary Incontinence, Stress
Interventions: SS-RBX; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 89
States / cities: Anchorage, Alaska • Sun City, Arizona • Tucson, Arizona + 78 more

Conditions: Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions: Lumbar Puncture, Blood Collection; Procedure
Lead sponsor: Biogen; Industry
Eligibility: Up to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Photoaging, Weight Loss, Skin Laxity, Photodamaged Skin, Volume Deficiency of the Midface
Interventions: Sculptra treatment, Restylane Treatment; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Advanced Solid Tumors
Interventions: E303; Drug
Lead sponsor: Samsung Bioepis Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Scottsdale, Arizona • Fairfax, Virginia

Conditions: Lung Cancer, Lung Metastases
Interventions: VGT-309; Drug
Lead sponsor: Vergent Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Duarte, California • Orlando, Florida • Rochester, Minnesota + 2 more

Conditions: Sarcoma
Interventions: RO5045337, doxorubicin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Santa Monica, California • Boston, Massachusetts • Hackensack, New Jersey + 2 more

Conditions: Healthy
Interventions: LX4211 400 mg, LX4211 800 mg, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colitis, Ulcerative
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more

Conditions: Cystectomy
Interventions: tissue procurement; Other
Lead sponsor: Tengion; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clostridium Difficile Infection
Interventions: Comparison between GenePOC PCR and Reference Method; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan + 2 more

Search by objective public record fields.

Mylan Insulin Glargine Study

Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Validation of an Obstacle Course Used in Patients With Muscle Tightness

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

MS Symptom Management Study

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Modifiable Variables in Parkinsonism (MVP)

A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)

An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

Angelman Syndrome (AS) Biomarker Study

Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery

Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains